View printer-friendly version |
Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure
Signs collaboration agreement with
Charles River will place scientists-in-residence at AstraZeneca’s
Charles
River will debut its enhanced HTS offering, which includes a recent
expansion of its in-house compound library, during SLAS2018, the annual
flagship conference for the
Additionally,
Approved Quotes
- “Providing our clients access to AstraZeneca’s HTS technology enhances our existing capabilities by broadening our assay platforms and increasing our ability to automate, ultimately allowing us to execute HTS projects with greater speed and accuracy.” –Ian Waddell, Ph.D., Executive Director, Biology at Charles River
-
“Through our longstanding relationship with
AstraZeneca , we have developed and implemented best practices that allow us to complete studies more efficiently and effectively. Access to AstraZeneca’s HTS technology is another collaboration that will enable us to continue to deliver groundbreaking science.” –Brian Bathgate, Ph.D., Corporate Senior Vice President, European Safety Assessment at Charles River -
“We look forward to welcoming Charles River’s scientists to our
state-of-the-art facilities in the
UK Centre for Lead Discovery . This demonstrates AstraZeneca’s open and collaborative approach to drug discovery and further establishes theUK Centre for Lead Discovery as a leading global centre for Hit Discovery.” –Mark Wigglesworth, Director High Throughput Screening at AstraZeneca’s IMED Biotech Unit
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180201005110/en/
Source:
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com